Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases.  The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Type
Public
HQ
Cleveland, US
Founded
1995
Size (employees)
60 (est)
Athersys was founded in 1995 and is headquartered in Cleveland, US
Report incorrect company information

Key People/Management at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Controller
Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Canton and Cleveland
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St
Show all (2)
Report incorrect company information

Athersys Financials and Metrics

Athersys Financials

Athersys's revenue was reported to be $3.71 m in FY, 2017
USD

Revenue (FY, 2017)

3.7 m

EBIT (FY, 2017)

(33.3 m)

Market capitalization (18-Apr-2018)

226.3 m

Cash (31-Dec-2017)

29.3 m
Athersys's current market capitalization is $226.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.4 m1.6 m11.9 m17.3 m3.7 m

Revenue growth, %

(33%)636%45%

General and administrative expense

8.5 m

R&D expense

27.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

621 k707 k388 k293 k731 k216 k396 k15.5 m595 k311 k1.5 m669 k

General and administrative expense

1.5 m1.8 m1.8 m1.7 m1.9 m1.9 m1.9 m2 m2 m1.8 m2.1 m2.2 m

R&D expense

4.7 m6.2 m5.8 m5.8 m5.7 m5.3 m5.1 m6.7 m5.8 m5.3 m5.6 m4.6 m

Operating expense total

6.2 m8.1 m7.7 m7.6 m7.6 m7.3 m7.1 m8.7 m7.9 m7.2 m7.9 m7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

31.9 m26.1 m23 m14.8 m29.3 m

Accounts Receivable

520 k694 k361 k598 k739 k

Current Assets

32.9 m27.2 m23.8 m16.3 m31.2 m

Total Assets

34.2 m28.7 m25.1 m19.1 m33.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

17.8 m45 m38.8 m32.4 m35.5 m32.3 m28.5 m30.4 m13.8 m8.3 m31.9 m28.6 m

Accounts Receivable

453 k894 k715 k665 k298 k1.8 m

Current Assets

18.6 m46.2 m39.8 m33.4 m38.7 m35.1 m29.2 m31.5 m25.7 m20.5 m34.9 m30.1 m

Total Assets

19.9 m47.6 m41.1 m34.8 m40.2 m36.5 m30.6 m33 m27.9 m23.3 m37.6 m32.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.7 m)(22.1 m)(16.4 m)(15.3 m)(32.2 m)

Depreciation and Amortization

346 k360 k267 k382 k684 k

Accounts Payable

(196 k)335 k(296 k)2.4 m1.5 m

Cash From Operating Activities

(22.8 m)(25.8 m)(13.8 m)(10.9 m)(24 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(5.6 m)

Depreciation and Amortization

86 k89 k93 k91 k70 k65 k66 k68 k67 k114 k164 k

Accounts Payable

2.8 m2.9 m2.7 m2.3 m2.6 m3.3 m4.2 m3.6 m6.6 m
USDY, 2017

Revenue/Employee

61.8 k

Financial Leverage

1.4 x
Show all financial metrics

Athersys Operating Metrics

Athersys's Patent Applications was reported to be 170 in FY, 2016.
FY, 2016

Patent Applications

170

Patents (US)

21

Patents Issued

200
Show all operating metrics
Report incorrect company information

Athersys News and Updates

BRIEF-Healios K.K. Reports 8.7 Pct Stake In Athersys

* HEALIOS K.K. REPORTS 8.7 PERCENT STAKE IN ATHERSYS INC AS OF MARCH 13, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2G0glmi)

Regenerative Medicine Global Market 2018: Key Players – Shire Pharmaceuticals, Advanced Cell Technology, Inc, Genzyme, Athersys, Inc., Kinetic Concepts, Inc.

Regenerative Medicine Market 2018 Global Analysis, Opportunities and Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information